PRECISIONadvisors

PRECISIONadvisors utilizes unique analytics-based solutions to inform patient journeys, payer projections, as well as global pricing, contracting, and market-access strategies. Schedule a meeting with our team via the event app or by reaching out to Carolyn Mcgrail directly below.

Join our insightful session "Cell and gene therapies – promise unfulfilled?" by the esteemed Richard Macaulay, Senior Vice President, PRECISIONadvisors taking place on March 12th at 12:05pm.

Richard will discuss how regenerative medicines offers huge promise to revolutionise healthcare, providing transformational benefits for patients for severe diseases with few/no treatment alternatives. However, the commercialisation of these innovations has been beset by many novel issues not typically faced by traditional biologics or small molecule medicines. Many of these challenges stem from these medicines’ very high-cost, one-time nature of treatment, and uncertainty in their long-term outcomes. But regenerative medicines have also faced significant challenges in identifying the right patients (due to safety, disease progression, and immunogenicity), data that a proportion of patients require additional therapies after gene therapy administration, challenges in commercial upscaling and roll-out, as well as their unique market dynamics. Regenerative medicines are also starting to move from rare diseases with no/few treatment options into more prevalent diseases with existing standards of care. Further, we will see increasing competition between cell and gene therapies operating in the same indication. This presentation will deep dive into some of the more novel challenges faced by companies in the CGT space and discuss strategies for companies to best mitigate these going forwards.

We pair decades of practical payer experience with deep analytics expertise to guide your biopharmaceutical innovation to peak market access. Our uniquely robust global pricing and market-access support includes evidence-based value demonstration, targeted pricing and access strategies, and distribution network optimization, all delivered by a team of industry-leading experts.

At this conference, PRECISIONadvisors is presenting in the Advanced Therapies track. We know that delivering a cell or gene therapy to market requires a nuanced, comprehensive and integrated approach, scientific and manufacturing expertise, and the right partner. That’s precisely why we’ve launched Precision ADVANCE, a collection of interconnected services and complementary teams uniquely focus on the complexities of clinical, regulatory, manufacturing, and commercial needs to successfully bring cell or gene therapies to market. Learn more about how we accelerate clinical development with Precision for Medicine, optimize next-gen manufacturing with Project Farma and drive commercial success with Precision Value & Health.